Here’s a second article from C3 research advocate, Pam McAllister, based on information she learned at the 2010 GI Cancers Symposium in Orlando.
Pam’s experience with colorectal cancer research advocacy goes back more than a decade. She has been a patient advocate with several cancer cooperative groups and now chairs the Radiation Therapy Oncology Group (RTOG) Patient Advocacy Committee.
While most patients with stage II colon cancer are at low risk of recurrence, there are patients in this group who are at increased risk and who may need chemotherapy to reduce their risk. Read the rest of this entry »